(Q37999967)

26 August 2017

From genes to drugs: targeted strategies for melanoma (English)

1 reference

Author Correction: From genes to drugs: targeted strategies for melanoma

26 August 2017

corrigendum / erratum

1 reference

1

Keith T Flaherty

1 reference

26 August 2017

3

David E Fisher

1 reference

26 August 2017

2

F Stephen Hodi

1 reference

26 August 2017

language of work or name

English

0 references

publication date

5 April 2012

1 reference

26 August 2017

Nature Reviews Cancer

1 reference

26 August 2017

12

1 reference

26 August 2017

349-361

1 reference

26 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc3218

26 August 2017

0 references

cites work

A novel transforming gene in a human malignant melanoma cell line

1 reference

N-ras mutations in human cutaneous melanoma from sun-exposed body sites.

31 March 2020

1 reference

Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma

31 March 2020

1 reference

Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

31 March 2020

1 reference

Recurrent patterns of dual RB and p53 pathway inactivation in melanoma

31 March 2020

1 reference

BRAF alterations are associated with complex mutational profiles in malignant melanoma.

31 March 2020

1 reference

Distinct sets of genetic alterations in melanoma

31 March 2020

1 reference

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas

31 March 2020

1 reference

Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression

31 March 2020

1 reference

Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness.

31 March 2020

1 reference

HOXB7 constitutively activates basic fibroblast growth factor in melanomas

31 March 2020

1 reference

The melanocyte differentiation program predisposes to metastasis after neoplastic transformation

31 March 2020

1 reference

Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy

31 March 2020

1 reference

MITF: master regulator of melanocyte development and melanoma oncogene

31 March 2020

1 reference

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

31 March 2020

1 reference

Lineage-specific signaling in melanocytes. C-kit stimulation recruits p300/CBP to microphthalmia.

31 March 2020

1 reference

Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF.

31 March 2020

1 reference

A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma

31 March 2020

1 reference

Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability

31 March 2020

1 reference

Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF

31 March 2020

1 reference

Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage

31 March 2020

1 reference

MITF pathway mutations in melanoma.

31 March 2020

1 reference

KIT as a therapeutic target in metastatic melanoma

31 March 2020

1 reference

KIT gene mutations and copy number in melanoma subtypes

31 March 2020

1 reference

Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors

31 March 2020

1 reference

Imatinib targeting of KIT-mutant oncoprotein in melanoma.

31 March 2020

1 reference

Major response to imatinib mesylate in KIT-mutated melanoma.

31 March 2020

1 reference

Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation

31 March 2020

1 reference

The GIST paradigm: lessons for other kinase-driven cancers

31 March 2020

1 reference

Characterization of mutagen-activated cellular oncogenes that confer anchorage independence to human fibroblasts and tumorigenicity to NIH 3T3 cells: sequence analysis of an enzymatically amplified mutant HRAS allele

31 March 2020

1 reference

Mechanism of activation of an N-ras oncogene of SW-1271 human lung carcinoma cells

31 March 2020

1 reference

Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells.

31 March 2020

1 reference

In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo.

31 March 2020

1 reference

Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy

31 March 2020

1 reference

New insight into BRAF mutations in cancer

31 March 2020

1 reference

Role of Raf in vascular protection from distinct apoptotic stimuli

31 March 2020

1 reference

Mutations of the BRAF gene in human cancer

31 March 2020

1 reference

CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations

31 March 2020

1 reference

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

31 March 2020

1 reference

BRAFE600-associated senescence-like cell cycle arrest of human naevi

31 March 2020

1 reference

V599EB-RAF is an oncogene in melanocytes

31 March 2020

1 reference

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma

31 March 2020

1 reference

BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma.

31 March 2020

1 reference

Oncogenic Braf induces melanocyte senescence and melanoma in mice

31 March 2020

1 reference

B-RAF is a therapeutic target in melanoma

31 March 2020

1 reference

Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference.

31 March 2020

1 reference

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

31 March 2020

1 reference

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

31 March 2020

1 reference

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

31 March 2020

1 reference

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

31 March 2020

1 reference

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

31 March 2020

1 reference

BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells

31 March 2020

1 reference

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors

31 March 2020

1 reference

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

31 March 2020

1 reference

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

31 March 2020

1 reference

The Crystal Structure of BRAF in Complex with an Organoruthenium Inhibitor Reveals a Mechanism for Inhibition of an Active Form of BRAF Kinase

31 March 2020

1 reference

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885

31 March 2020

1 reference

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

31 March 2020

1 reference

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

31 March 2020

1 reference

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

31 March 2020

1 reference

Oncogene activation in human benign tumors of the skin (keratoacanthomas): is HRAS involved in differentiation as well as proliferation?

31 March 2020

1 reference

Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin

31 March 2020

1 reference

Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.

31 March 2020

1 reference

MEK1 mutations confer resistance to MEK and B-RAF inhibition

31 March 2020

1 reference

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

31 March 2020

1 reference

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

31 March 2020

1 reference

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

31 March 2020

1 reference

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

31 March 2020

1 reference

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

31 March 2020

1 reference

BRAF mutation predicts sensitivity to MEK inhibition

31 March 2020

1 reference

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi

31 March 2020

1 reference

PTEN signaling pathways in melanoma

31 March 2020

1 reference

Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin

31 March 2020

1 reference

The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma

31 March 2020

1 reference

Deregulated Akt3 activity promotes development of malignant melanoma

31 March 2020

1 reference

An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells.

31 March 2020

1 reference

Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells

31 March 2020

1 reference

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium

31 March 2020

1 reference

Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice

31 March 2020

1 reference

Genomic profiling of malignant melanoma using tiling-resolution arrayCGH.

31 March 2020

1 reference

A cell cycle regulator potentially involved in genesis of many tumor types

31 March 2020

1 reference

Effects on proliferation and melanogenesis by inhibition of mutant BRAF and expression of wild-type INK4A in melanoma cells.

31 March 2020

1 reference

Amplification of CDK4 and MDM2 in malignant melanoma.

31 March 2020

1 reference

Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer

31 March 2020

1 reference

Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression

31 March 2020

1 reference

Expression of platelet-derived growth factor (PDGF)-A, PDGF-B and the PDGF-alpha receptor, but not the PDGF-beta receptor, in human malignant melanoma in vivo

31 March 2020

1 reference

Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB

31 March 2020

1 reference

Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma.

31 March 2020

1 reference

Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival

31 March 2020

1 reference

A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.

31 March 2020

1 reference

Model predicting survival in stage I melanoma based on tumor progression

31 March 2020

1 reference

Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion

31 March 2020

1 reference

New tumor antigens recognized by T cells

31 March 2020

1 reference

Presence on a human melanoma of multiple antigens recognized by autologous CTL.

31 March 2020

1 reference

A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma

31 March 2020

1 reference

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

31 March 2020

1 reference

Tumor-specific shared antigenic peptides recognized by human T cells

31 March 2020

1 reference

The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

31 March 2020

1 reference

A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

31 March 2020

1 reference

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

31 March 2020

1 reference

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

31 March 2020

1 reference

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection

31 March 2020

1 reference

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes

31 March 2020

1 reference

Immunological detection of altered signaling molecules involved in melanoma development

31 March 2020

1 reference

A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes

31 March 2020

1 reference

A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma

31 March 2020

1 reference

Peptide-based cancer vaccines

31 March 2020

1 reference

Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity

31 March 2020

1 reference

Review: dendritic cell-based vaccine in the treatment of patients with advanced melanoma

31 March 2020

1 reference

Dendritic cells: a journey from laboratory to clinic

31 March 2020

1 reference

Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells.

31 March 2020

1 reference

Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control

31 March 2020

1 reference

Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells

31 March 2020

1 reference

Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells

31 March 2020

1 reference

Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells

31 March 2020

1 reference

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy

31 March 2020

1 reference

CpG motifs: the active ingredient in bacterial extracts?

31 March 2020

1 reference

NKT cells - conductors of tumor immunity?

31 March 2020

1 reference

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

31 March 2020

1 reference

Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.

31 March 2020

1 reference

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

31 March 2020

1 reference

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

31 March 2020

1 reference

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

31 March 2020

1 reference

The central role of CD4(+) T cells in the antitumor immune response

31 March 2020

1 reference

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma

31 March 2020

1 reference

Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.

31 March 2020

1 reference

Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells

31 March 2020

1 reference

Enhancement of antitumor immunity by CTLA-4 blockade

31 March 2020

1 reference

Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy

31 March 2020

1 reference

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

31 March 2020

1 reference

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

31 March 2020

1 reference

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

31 March 2020

1 reference

The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation

31 March 2020

1 reference

Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings.

31 March 2020

1 reference

Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment

31 March 2020

1 reference

Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies

31 March 2020

1 reference

CTLA-4: negative regulator of the immune response and a target for cancer therapy

31 March 2020

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

31 March 2020

1 reference

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

31 March 2020

1 reference

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

31 March 2020

1 reference

PD-1 ligands, negative regulators for activation of naive, memory, and recently activated human CD4+ T cells.

31 March 2020

1 reference

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

31 March 2020

1 reference

TNF/TNFR family members in costimulation of T cell responses

31 March 2020

1 reference

CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion

31 March 2020

1 reference

Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species

31 March 2020

1 reference

Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients

31 March 2020

1 reference

New insights into the role of 4-1BB in immune responses: beyond CD8+ T cells

31 March 2020

1 reference

Immune responses in 4-1BB (CD137)-deficient mice

31 March 2020

1 reference

DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy

31 March 2020

1 reference

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

31 March 2020

1 reference

A translational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cell immunotherapy

31 March 2020

1 reference

Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand.

31 March 2020

1 reference

Somatic activation of KIT in distinct subtypes of melanoma

31 March 2020

1 reference

Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.

31 March 2020

1 reference

Detection of copy number alterations in metastatic melanoma by a DNA fluorescence in situ hybridization probe panel and array comparative genomic hybridization: a southwest oncology group study (S9431).

31 March 2020

1 reference

Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases

31 March 2020

1 reference

An oncogenic role for ETV1 in melanoma

31 March 2020

1 reference

Frequent p16-independent inactivation of p14ARF in human melanoma

31 March 2020

1 reference

Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations

31 March 2020

1 reference

Frequent mutation of BAP1 in metastasizing uveal melanomas

31 March 2020

1 reference

Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays.

31 March 2020

1 reference

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification

31 March 2020

1 reference

Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma.

31 March 2020

1 reference

A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma

31 March 2020

1 reference

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

31 March 2020

1 reference

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

31 March 2020

1 reference

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

31 March 2020

1 reference

Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine

31 March 2020

1 reference

12 December 2020

Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts

1 reference

12 December 2020

Peptide-binding heat shock proteins in the endoplasmic reticulum: role in immune response to cancer and in antigen presentation.

1 reference

12 December 2020

Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules

1 reference

12 December 2020

Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system

1 reference

12 December 2020

Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization

1 reference

12 December 2020

Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)

1 reference

12 December 2020

Genetically modified tumor cell vaccines

1 reference

12 December 2020

Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma.

1 reference

12 December 2020

Immunohistochemical determination of vascular endothelial growth factor (VEGF) overexpression in malignant melanoma

1 reference

12 December 2020

Suppression of BRAF(V599E) in human melanoma abrogates transformation

1 reference

12 December 2020

Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells

1 reference

12 December 2020

c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi.

1 reference

12 December 2020

Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity

1 reference

12 December 2020

Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression

1 reference

12 December 2020

Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC3218

1 reference

Dimensions Publication ID

26 August 2017

0 references

1 reference